Investment will allow NeuroTherapia to develop orally-available treatment for neurodegenerative disease. CLEVELAND, September 22, 2020-- NeuroTherapia, Inc., a clinical-stage company focused on developing therapies for neurodegenerative diseases, announced today the closing of its Series A financing of $8.8M. The Series A round, led by Brain Trust Accelerator Fund II, included investments from The Cleveland Clinic Foundation, Dolby Family Ventures and Alzheimer's Drug Discovery Foundation. NeuroTherapia is developing an orally available cannabinoid receptor agonist, NTRX-07, for the treatment of neuroinflammation, which likely plays a critical role in the progression of neurodegenerative diseases.